{
  "title": "Paper_1102",
  "abstract": "pmc Vaccines (Basel) Vaccines (Basel) 2764 vaccines vaccines Vaccines 2076-393X Multidisciplinary Digital Publishing Institute  (MDPI) PMC12474334 PMC12474334.1 12474334 12474334 41012173 10.3390/vaccines13090970 vaccines-13-00970 1 Review Engineering Universal Cancer Immunity: Non-Tumor-Specific mRNA Vaccines Trigger Epitope Spreading in Cold Tumors Magoola Matthias 1 https://orcid.org/0000-0002-0513-0336 Niazi Sarfaraz K. 2 * Storkus Walter J. Academic Editor 1 mm@dei.bio 2 * niazi@chicagou.edu 12 9 2025 9 2025 13 9 497676 970 06 8 2025 25 8 2025 08 9 2025 12 09 2025 28 09 2025 29 09 2025 © 2025 by the authors. 2025 https://creativecommons.org/licenses/by/4.0/ Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license ( https://creativecommons.org/licenses/by/4.0/ The landscape of cancer immunotherapy must shift from personalized neoantigen vaccines toward universal platforms that leverage innate immune activation. This review examines a novel mRNA vaccine strategy that encodes non-tumor-specific antigens, carefully selected pathogen-derived or synthetic sequences designed to transform immunologically “cold” tumors into inflamed therapy-responsive microenvironments. Unlike conventional approaches requiring patient-specific tumor sequencing and 8–12-week manufacturing timelines, this platform utilizes pathogen-associated molecular patterns (PAMPs) and damage-associated molecular patterns (DAMPs) to trigger broad innate immune activation through multiple pattern recognition receptors (PRRs). The key therapeutic mechanism is epitope spreading, where vaccine-induced inflammation reveals previously hidden tumor antigens, enabling the immune system to mount responses against cancer-specific targets without prior knowledge of these antigens. Delivered via optimized lipid nanoparticles (LNPs) or alternative polymer-based systems, these vaccines induce epitope spreading, enhance checkpoint inhibitor responsiveness, and establish durable antitumor memory. This approach offers several potential advantages, including immediate treatment availability, a cost reduction of up to 100-fold compared to personalized vaccines, scalability for global deployment, and efficacy across diverse tumor types. However, risks such as cytokine release syndrome (CRS), potential for off-target autoimmunity, and challenges with pre-existing immunity must be addressed. By eliminating barriers of time, cost, and infrastructure, this universal platform could help democratize access to advanced cancer treatment, potentially benefiting the 70% of cancer patients in low- and middle-income countries (LMICs) who currently lack immunotherapy options. mRNA vaccines cancer immunotherapy innate immunity lipid nanoparticles polymer delivery systems tumor microenvironment epitope spreading global health equity This research received no external funding. pmc-status-qastatus 0 pmc-status-live yes pmc-status-embargo no pmc-status-released yes pmc-prop-open-access yes pmc-prop-olf no pmc-prop-manuscript no pmc-prop-legally-suppressed no pmc-prop-has-pdf yes pmc-prop-has-supplement no pmc-prop-pdf-only no pmc-prop-suppress-copyright no pmc-prop-is-real-version no pmc-prop-is-scanned-article no pmc-prop-preprint no pmc-prop-in-epmc yes 1. Introduction: The Evolution of mRNA-Based Cancer Immunotherapy 1.1. Current Landscape, Limitations, and Comparisons mRNA vaccines gained prominence through their applications in the SARS-CoV-2 pandemic [ 1 2 3 4 5 6 7 However, personalized approaches face several barriers: 8–12-week timelines for sequencing and production increase the risk of disease progression; costs exceed $150,000, limiting access; the accuracy of neoantigen prediction ranges from 2% to 5% [ 8 9 10 11 Counterarguments favor antigen-specific vaccines for precision in high-mutation tumors, potentially outperforming non-specific inflammation that could cause off-target effects or CRS. For instance, neoantigen vaccines have shown targeted responses in pancreatic cancer trials, although they are less scalable [ 12 13 1.2. Paradigm Shift: Non-Tumor-Specific Immune Activation Effective immunotherapy may rely on innate activation to reprogram the tumor microenvironment (TME) [ 14 15 16 17 2. Mechanistic Foundation: Innate Immunity and Epitope Spreading 2.1. Tumor Immune Phenotypes and Microenvironment Reprogramming Cold tumors (70% of solids) lack T-cell infiltration; hot tumors respond better [ 18 Table 1 2 2.2. Detailed Molecular Cascade of Epitope Spreading Epitope spreading represents a critical mechanism for generating broad antitumor immunity beyond the initially targeted antigens. This phenomenon occurs through a precisely orchestrated molecular cascade initiated by vaccine-induced activation of the innate immune system ( Figure 1 Phase 1: Initial Immune Activation (0–6 h) 25 Phase 2: APC Maturation and Antigen Processing (6–24 h) 26 Phase 3: Cross-Presentation and T Cell Priming (24–72 h) 27 Phase 4: Epitope Diversification (3–14 days) 28 2.3. Key Cellular Players in Epitope-Spreading Initiation Conventional Dendritic Cells (cDC1) are characterized by CD103+ expression in tissues and CD141+ (BDCA3+) in human blood, making them the master regulators of cross-presentation. These cells express high levels of XCR1, making them responsive to XCL1 and XCL2 chemokines produced by activated NK cells and CD8+ T cells. Upon mRNA vaccine stimulation, cDC1 cells undergo rapid maturation, upregulating CD40, CD80, and CD86 while maintaining their superior cross-presentation capacity through enhanced expression of SEC22B and WDFY4 [ 29 Table 2 Figure 2 3. Alternative Immune Activation Pathways Beyond Type I Interferons 3.1. Inflammasome-Mediated Immunity and Pathway Cross-Talk The inflammasome complex represents a critical complementary pathway that can synergize with or potentially antagonize type I interferon responses. Understanding these interactions is crucial for designing optimal vaccines. Synergistic Interactions: 30 Potential Antagonistic Effects. 31 Figure 3 Table 3 3.2. Metabolic Reprogramming Integration The metabolic reprogramming pathway intersects with both interferon and inflammasome signaling to create a comprehensive immune-activation program. Key integration points include ( Table 4 mTOR-AMPK Checkpoint Integration 35 Metabolic Competition Resolution 36 vaccines-13-00970-t004_Table 4 Table 4 Metabolic Reprogramming Strategies in mRNA Cancer Vaccines. Metabolic Pathway Target Enzyme/Protein mRNA Encoding Strategy Immune Effects Validation Status References Glycolysis HK2, PFKFB3 Constitutively active forms Enhanced T-cell effector function Preclinical proof of concept [ 37 Oxidative phosphorylation PGC-1α, TFAM Mitochondrial biogenesis factors Memory T-cell formation Mouse models validated [ 38 Fatty acid oxidation CPT1A (mutant) Malonyl-CoA resistant Sustained T-cell responses In vitro validation [ 39 One-carbon metabolism MTHFD2, SHMT2 Folate cycle enzymes T-cell proliferation Early development [ 40 Amino acid metabolism CAT-1, ASCT2 Nutrient transporters Overcome TME depletion Preclinical testing [ 36 NAD+ metabolism NAMPT, NMNAT NAD+ synthesis Prevent exhaustion Clinical biomarker [ 41 3.3. Tissue-Resident Memory Programming The induction of tissue-resident memory T cells (TRM) represents an emerging frontier in cancer vaccine development. Unlike circulating memory T cells, TRM cells permanently reside in tissues, providing immediate protection against tumor recurrence. Recent studies have shown that mRNA vaccine formulations and delivery routes have a profound influence on TRM formation [ 42 Figure 3 Table 5 4. Platform Design and Antigen Selection 4.1. Addressing Pre-Existing Immunity Challenges A critical concern with using pathogen-derived antigens is the potential for pre-existing immunity to accelerate vaccine clearance and reduce efficacy. Most individuals possess immunity to common pathogens through natural infection or vaccination, which could theoretically neutralize the vaccine before immune activation occurs. Mechanisms of Pre-existing Immunity Impact 47  Mitigation Strategies Modified Pathogen Antigens 48 Consensus and Chimeric Sequences 49 Synthetic Immunogens: 50 Clinical Evidence for Mitigation Success 51 Table 6 4.2. Advanced Antigen Selection Criteria The selection process has been refined based on clinical experience and mechanistic understanding: Enhanced Immunogenicity Metrics 52 Safety Enhancement Factors: 53 vaccines-13-00970-t006_Table 6 Table 6 Characteristics of Candidate Non-Tumor-Specific Antigens for Universal mRNA Cancer Vaccines. Antigen Category Specific Example HLA Coverage (%) Safety Profile PRR Activation Manufacturing Score Clinical Status References Modified viral proteins SARS-CoV-2 Spike (modified) 85–90 Proven in billions TLR7/8, RIG-I High Phase II trials [ 48 54 Consensus viral proteins Influenza HA consensus 80–85 Decades of use TLR7/8, RIG-I High Phase I completed [ 55 Modified bacterial antigens Flagellin (modified) 75–80 Clinical trials TLR5, NLRC4 Medium Phase I ongoing [ 24 Bacterial heat shock proteins HSP70 (low homology) 70–75 Preclinical safety TLR2/4 Medium Preclinical [ 56 Synthetic multi-epitope Computationally designed > 90 In development Multiple High Design phase [ 50 57 Pathogen-associated proteins Modified OmpA 75–85 Preclinical TLR2/4 Medium Research [ 58 4.3. mRNA Design and Optimization The optimization of mRNA design represents a critical factor in vaccine efficacy, requiring careful balance between enhancing stability and reducing innate immune recognition while preserving immunogenicity. Chemical Modifications 59 UTR Engineering 60 Codon Optimization Strategies. 61 5. Delivery System Optimization: Beyond Lipid Nanoparticles 5.1. Addressing LNP Limitations: Liver Tropism and Alternative Systems A significant challenge with current LNP technology is the rapid and predominant accumulation in the liver after systemic administration, with up to 60% of the administered dose concentrating in hepatocytes within 30 min of intravenous injection [ 62 Table 7 Mechanisms of Liver Tropism 63  Strategies to Overcome Liver Tropism Selective Organ-Targeting Lipids 64 Transient Stealth Coating Strategies 65 Alternative Administration Routes: 66 5.2. Promising Polymer-Based Alternative Delivery Systems Polymer-based carriers represent a compelling alternative to LNPs, potentially circumventing several inherent limitations while offering unique advantages for mRNA delivery. Polyethylenimine (PEI) Systems 67 Poly(β-amino ester) (PBAE) Carriers 68 Chitosan-based systems 69 5.3. RNase Resistance Strategies A significant challenge for all systemic mRNA delivery platforms is ensuring sufficient resistance to ribonuclease (RNase) degradation [ 70 Chemical Modifications for Stability 71 Protective formulation strategies require complete 72 Structural RNA Engineering 73 vaccines-13-00970-t007_Table 7 Table 7 Comparison of Delivery Systems for mRNA Cancer Vaccines. Delivery System Advantages Limitations RNase Protection Liver Avoidance Manufacturing Clinical Status References Traditional LNPs Proven efficacy, FDA approved Liver tropism, inflammation High (>95%) Low Established Clinical use [ 74 Targeted LNPs Organ-specific delivery Complex synthesis, cost High (>95%) Moderate–High Development Phase I [ 64 PEI Systems Enhanced escape, versatile Potential toxicity concern Moderate (70–85%) High Scalable Phase I [ 67 PBAE Polymers Biodegradable, tunable Limited clinical data Moderate (70–85%) High Emerging Preclinical [ 68 Chitosan Systems Natural, immunostimulatory Variable quality, consistency Low (50–70%) High Established Preclinical [ 69 Hybrid Systems Combined advantages Complexity, characterization High (85–95%) Moderate Research Research [ 75 6. Translational Considerations and Clinical Development 6.1. Interspecies Scaling and Human Dose Prediction The proposed Phase I dose range of 25–200 μg requires careful justification based on preclinical data and established scaling methodologies [ 76 Table 8 6.2. Considerations for Slow-Growing Human Tumors The translation from rapidly growing murine tumor models to slow-growing human tumors presents significant challenges [ 77 7. Preclinical Validation Results 7.1. Immunogenicity and Safety Profile Recent preclinical studies have provided compelling evidence for the efficacy of non-tumor-specific mRNA vaccines in murine tumor models [ 78 Table 9 7.2. Evidence of Epitope Spreading The demonstration of epitope spreading provides the most compelling mechanistic validation for the universal vaccine approach [ 83 Table 10 7.3. Synergy with Checkpoint Inhibitors The combination of universal mRNA vaccines with checkpoint inhibitor therapy demonstrated remarkable synergy across multiple preclinical models [ 84 7.4. Safety and Biodistribution Analysis Comprehensive toxicology studies established the safety profile necessary for clinical translation [ 85 8. Comparison with Current Approaches 8.1. Personalized Neoantigen Vaccines The mRNA-4157/V940 platform represents the current state-of-the-art in personalized cancer vaccines [ 86 Table 11 8.2. Shared Antigen Vaccines Several shared antigen vaccines provide relevant comparisons [ 87 88 8.3. Cytokine-Encoding mRNA Vaccines Alternative mRNA approaches using direct cytokine encoding provide mechanistic comparisons [ 89 9. Clinical Translation Strategy 9.1. Regulatory Pathway and Guidelines The regulatory pathway for universal mRNA cancer vaccines benefits significantly from the COVID-19 vaccine precedents [ 90 Table 12 9.2. Phase I Clinical Trial Design The first-in-human study design strikes a balance between comprehensive safety evaluation and efficient dose finding [ 91 9.3. Biomarker Strategy and Correlative Studies A comprehensive biomarker program will support dose selection and patient stratification [ 92 Table 13 10. Manufacturing and Global Access Considerations 10.1. Scalable Manufacturing Platform The global expansion of mRNA manufacturing capacity provides a foundation for cancer vaccine production [ 93 Table 14 10.2. Cost-Effectiveness and Health Economics Comprehensive economic modeling demonstrates favorable cost-effectiveness ratios [ 94 10.3. Stability and Storage Solutions Current ultra-cold storage requirements represent a significant barrier to global deployment [ 95 11. Challenges and Future Directions 11.1. Key Challenges and Mitigation Strategies Despite promising preclinical results, several significant challenges must be addressed [ 96 Table 15 11.2. Future Research Priorities The next generation of universal mRNA cancer vaccines will integrate advanced technologies [ 97 Table 16 11.3. Long-Term Vision and Goals The goal extends beyond individual patient treatment to the transformation of global cancer care [ 98 12. Conclusions The development of universal mRNA vaccines encoding non-tumor-specific antigens represents a fundamental paradigm shift in cancer immunotherapy, moving beyond the limitations of personalized approaches toward broadly applicable, immediately available treatments that leverage innate immune activation to generate comprehensive antitumor responses. 12.1. Scientific Foundation and Mechanistic Innovation This comprehensive review has established the robust scientific foundation underlying the universal vaccine approach. The detailed characterization of epitope-spreading mechanisms reveals a precisely orchestrated cascade involving multiple immune pathways that can be strategically manipulated through vaccine design. 12.2. Technological Solutions and Clinical Translation The comprehensive analysis of delivery system optimization addresses critical barriers to clinical success. The recognition of liver tropism as a major limitation of current LNP technology has driven innovation in alternative delivery approaches. 12.3. Global Health Impact and Access Solutions The most transformative aspect of the universal vaccine platform lies in its potential to democratize access to advanced cancer immunotherapy. The 100-fold cost reduction compared to personalized approaches fundamentally changes the economics of cancer care. 12.4. Limitations and Future Development Needs While the preclinical evidence strongly supports the universal vaccine approach, important limitations must be acknowledged. The predominance of murine tumor model data necessitates careful clinical validation in human patients. 12.5. Future Research Priorities and Innovation Opportunities The next generation of universal cancer vaccines will integrate advanced technologies, including artificial intelligence for antigen design and patient selection, next-generation RNA architectures for enhanced stability and function, and sophisticated delivery systems for tissue-specific targeting. 12.6. Concluding Perspective The universal mRNA cancer vaccine platform represents more than a technological advance—it embodies a moral imperative to ensure that the benefits of scientific progress reach those who need them most. Through unwavering commitment to both scientific excellence and global health equity, universal mRNA cancer vaccines may fulfill their promise of harnessing the immune system to defeat cancer for all patients, regardless of geographic location, economic status, or healthcare infrastructure. Disclaimer/Publisher’s Note: Author Contributions M.M.: Conceptualization, research, conclusions; S.K.N.: Conceptualization, research, writing, and artwork. All authors have read and agreed to the published version of the manuscript. Conflicts of Interest M.M. is an inventor and developer of biological drugs, including mRNA vaccines; S.K.N. is an advisor to the US FDA, EMA, MHRA, the US Senate, the White House, and heads of multiple sovereign states, and is a developer of novel biological drugs, including cancer vaccines. Abbreviations CRS: Cytokine Release Syndrome—Excessive immune activation leading to systemic inflammation; DC: Dendritic Cell—Antigen-presenting immune cell critical for T-cell priming; DAMP: Damage-Associated Molecular Pattern—Endogenous signals released during cellular stress to alert the immune system; LNP: Lipid Nanoparticle—Nanoscale delivery system for mRNA, enabling cellular uptake and endosomal escape; PAMP: Pathogen-Associated Molecular Pattern—Microbial components that trigger innate immune responses via PRRs; PRR: Pattern Recognition Receptor—Immune sensors (e.g., TLRs, RIG-I) that detect PAMPs and DAMPs; TME: Tumor Microenvironment—The cellular and molecular ecosystem surrounding tumors, often immunosuppressive in cold tumors; TRM: Tissue-Resident Memory T Cell—Long-lived T cells residing in tissues for rapid local immune responses. References 1. Pardi N. Hogan M.J. Porter F.W. Weissman D. mRNA vaccines—A new era in vaccinology Nat. Rev. Drug Discov. 2018 17 261 279 10.1038/nrd.2017.243 29326426 PMC5906799 2. Mendez-Gomez H.R. DeVries A. Castillo P. von Roemeling C. Qdaisat S. Stover B.D. Xie C. Weidert F. Zhao C. Moor R. RNA aggregates harness the danger response for potent cancer immunotherapy Cell 2024 187 2521 2535 10.1016/j.cell.2024.04.003 38697107 PMC11767857 3. Weber J.S. Carlino M.S. Khattak A. Meniawy T. Ansstas G. Taylor M.H. Kim K.B. McKean M. Long G.V. Sullivan R.J. Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): A randomised, phase 2b study Lancet 2024 403 632 644 10.1016/S0140-6736(23)02268-7 38246194 4. Fiedler K. Lazzaro S. Lutz J. Rauch S. Heidenreich R. mRNA cancer vaccines Recent Results Cancer Res. 2016 209 61 84 10.1007/978-3-319-42934-2_5 28101688 5. Qdaisat S. Wummer B. Stover B.D. Zhang D. McGuiness J. Weidert F. Chardon-Robles J. Grippin A. DeVries A. Zhao C. Sensitization of tumours to immunotherapy by boosting early type-I interferon responses enables epitope spreading Nat. Biomed. Eng. 2025 10.1038/s41551-025-01380-1 40681861 6. UF Health Surprising Finding Could Pave Way for Universal Cancer Vaccine UF Health News Gainesville, FL, USA 2025 7. Lanese N. ‘Universal’ Cancer Vaccine Heading to Human Trials Could be Useful for ‘All Forms of Cancer’ Live Science New York City, NY, USA 2025 8. Bassani-Sternberg M. Bräunlein E. Klar R. Engleitner T. Sinitcyn P. Audehm S. Straub M. Weber J. Slotta-Huspenina J. Specht K. Direct identification of clinically relevant neoepitopes presented on native human melanoma tissue by mass spectrometry Nat. Commun. 2016 7 13404 10.1038/ncomms13404 27869121 PMC5121339 9. McGranahan N. Swanton C. Clonal heterogeneity and tumor evolution: Past, present, and the future Cell 2017 168 613 628 10.1016/j.cell.2017.01.018 28187284 10. Hollingsworth R.E. Jansen K. Turning the corner on therapeutic cancer vaccines Npj Vaccines 2019 4 7 10.1038/s41541-019-0103-y 30774998 PMC6368616 11. Wadhwa A. Aljabbari A. Lokras A. Foged C. Thakur A. Opportunities and challenges in the delivery of mRNA-based vaccines Pharmaceutics 2020 12 102 10.3390/pharmaceutics12020102 32013049 PMC7076378 12. Rojas L.A. Sethna Z. Soares K.C. Olcese C. Pang N. Patterson E. Lihm J. Ceglia N. Guasp P. Chu A. Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer Nature 2023 618 144 150 10.1038/s41586-023-06063-y 37165196 PMC10171177 13. Fritsch E.F. Burkhardt U.E. Hacohen N. Wu C.J. Personal Neoantigen Cancer Vaccines: A Road Not Fully Paved Cancer Immunol. Res. 2020 8 1465 1469 10.1158/2326-6066.CIR-20-0526 33262163 PMC7717540 14. Corrales L. Glickman L.H. McWhirter S.M. Kanne D.B. Sivick K.E. Katibah G.E. Woo S.-R. Lemmens E. Banda T. Leong J.J. Direct activation of STING in the tumor microenvironment leads to potent and systemic tumor regression and immunity Cell Rep. 2015 11 1018 1030 10.1016/j.celrep.2015.04.031 25959818 PMC4440852 15. Demaria S. Ng B. Devitt M.L. Babb J.S. Kawashima N. Liebes L. Formenti S.C. Ionizing radiation inhibition of distant untreated tumors (abscopal effect) is immune mediated Int. J. Radiat. Oncol. 2015 58 862 870 10.1016/j.ijrobp.2003.09.012 14967443 16. Vanderlugt C.L. Miller S.D. Epitope spreading in immune-mediated diseases: Implications for immunotherapy Nat. Rev. Immunol. 2002 2 85 95 10.1038/nri724 11910899 17. Andrews L.P. Yano H. Vignali D.A.A. Inhibitory receptors and ligands beyond PD-1, PD-L1 and CTLA-4: Breakthroughs or backups Nat. Immunol. 2020 20 1425 1434 10.1038/s41590-019-0512-0 31611702 18. Galon J. Bruni D. Approaches to treat immune hot, altered and cold tumours with combination immunotherapies Nat. Rev. Drug Discov. 2019 18 197 218 10.1038/s41573-018-0007-y 30610226 19. Kranz L.M. Diken M. Haas H. Kreiter S. Loquai C. Reuter K.C. Meng M. Fritz D. Vascotto F. Hefesha H. Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy Nature 2016 534 396 401 10.1038/nature18300 27281205 20. Lugrin J. Martinon F. Detection of cytosolic nucleic acids in sterile inflammation and inflammatory diseases Nat. Rev. Immunol. 2024 24 487 502 10.1038/s41577-023-00973-8 21. Yamasaki S. Ishikawa E. Sakuma M. Hara H. Ogata K. Saito T. Mincle is an ITAM-coupled activating receptor that senses damaged cells Nat. Immunol. 2008 9 1179 1188 10.1038/ni.1651 18776906 22. Miao L. Li L. Huang Y. Delcassian D. Chahal J. Han J. Shi Y. Sadtler K. Gao W. Lin J. Delivery of mRNA vaccines with heterocyclic lipids increases anti-tumor efficacy by STING-mediated immune cell activation Nat. Biotechnol. 2019 37 1174 1185 10.1038/s41587-019-0247-3 31570898 23. Li Y. Cao Q. Hu Y. He B. Cao T. Tang Y. Zhou X.P. Lan X.P. Liu S.Q. Advances in the interaction of glycolytic reprogramming with lactylation Biomed. Pharmacother. 2023 177 116982 10.1016/j.biopha.2024.116982 38906019 24. Bourquin C. Anz D. Zwiorek K. Lanz A.-L. Fuchs S. Weigel S. Wurzenberger C. von der Borch P. Golic M. Moder S. Targeting CpG oligonucleotides to the lymph node by nanoparticles elicits efficient antitumoral immunity J. Immunol. 2008 181 2990 2998 10.4049/jimmunol.181.5.2990 18713969 25. Darrah P.A. Patel D.T. De Luca P.M. Lindsay R.W.B. Davey D.F. Flynn B.J. Hoff S.T. Andersen P. Reed S.G. Morris S.L. Multifunctional TH1 cells define a correlate of vaccine-mediated protection against Leishmania major Nat. Med. 2007 13 843 850 10.1038/nm1592 17558415 26. Linsley P.S. Speake C. Whalen E. Chaussabel D. Castro M.G. Copy number loss of the interferon gene cluster in melanomas is linked to reduced T cell infiltrate and poor patient prognosis PLoS ONE 2014 9 e109760 10.1371/journal.pone.0109760 25314013 PMC4196925 27. Zhivaki D. Borriello F. Chow O.A. Doran B. Fleming I. Theisen D.J. Pallis P. Shalek A.K. Sokol C.L. Zanoni I. Inflammasomes within Hyperactive Murine Dendritic Cells Stimulate Long-Lived T Cell-Mediated Anti-tumor Immunity Cell Rep. 2020 33 108381 10.1016/j.celrep.2020.108381 33207188 PMC7727444 28. Kellermann G. Leulliot N. Cherfils-Vicini J. Blaud M. Brest P. Activated B-cells enhance epitope spreading to support successful cancer immunotherapy Front. Immunol. 2024 15 1382236 10.3389/fimmu.2024.1382236 38571942 PMC10989059 29. Tong G. Shen Y. Li H. Qian H. Tan Z. NLRC4 inflammasome in inflammatory bowel disease and cancer Nat. Rev. Gastroenterol. Hepatol. 2024 65 1 12 10.3892/ijo.2024.5687 30. Downs K.P. Nguyen H. Dorfleutner A. Stehlik C. An overview of the non-canonical inflammasome Mol. Asp. Med. 2020 76 100924 10.1016/j.mam.2020.100924 PMC7808250 33187725 31. Karki R. Man S.M. Kanneganti T.D. Inflammasomes and Cancer Cancer Immunol 2017 5 94 99 10.1158/2326-6066.CIR-16-0269 28093447 PMC5593081 32. Tay R.E. Richardson E.K. Toh H.C. Cytokine release syndrome in cancer immunotherapy: Mechanisms and man-agement Cancer Treat. Rev. 2024 122 102652 10.1016/j.ctrv.2023.102652 37980876 33. Robinson K.S. Toh G.A. Rozario P. Chua R. Bauernfried S. Sun Z. Firdaus M.J. Bayat S. Nadkarni R. Poh Z.S. ZAKα-driven ribotoxic stress response activates the human NLRP1 inflammasome Science 2022 377 328 335 10.1126/science.abl6324 35857590 PMC7614315 34. Nguyen C.M. Vu T.T. Nguyen M.N. Tran-Nguyen T.-S. Huynh C.T. Ha Q.T. Nguyen H.-N. Tran L.S. Neoantigen-based mRNA vaccine exhibits superior anti-tumor activity compared to synthetic long peptides in an in vivo lung carcinoma model Cancer Immunol. Immunother. 2025 74 145 10.1007/s00262-025-03992-7 40072566 PMC11949242 35. Biswas S.K. Metabolic Reprogramming of Immune Cells in Cancer Progression Immunity 2015 43 435 449 10.1016/j.immuni.2015.09.001 26377897 36. Yang L. Chu Z. Liu M. Zou Q. Li J. Liu Q. Wang Y. Wang T. Xiang J. Wang B. Amino acid metabolism in immune cells: Essential regulators of the effector functions, and promising opportunities to enhance cancer immunotherapy J. Hematol. Oncol. 2023 16 59 10.1186/s13045-023-01453-1 37277776 PMC10240810 37. Steinert E.M. Vasan K. Chandel N.S. Mitochondrial Metabolism Regulation of T Cell-Mediated Immunity Annu. Rev. Immunol. 2021 39 395 416 10.1146/annurev-immunol-101819-082015 33902315 PMC10403253 38. Raud B. McGuire P.J. Jones R.G. Sparwasser T. Berod L. Fatty acid oxidation in CD8+ T cell memory Immunol. Rev. 2024 317 123 139 10.1111/imr.13288 PMC6691976 29664569 39. Kurniawan H. Kobayashi T. Brenner D. The emerging role of one-carbon metabolism in T cells Curr. Opin. Biotechnol. 2021 68 193 201 10.1016/j.copbio.2020.12.001 33422815 40. Oliveres H. Cascante M. Maurel J. Metabolic interventions to enhance immunotherapy and targeted therapy efficacy in advanced colorectal cancer Curr. Opin. Chem. Biol. 2023 77 102401 10.1016/j.cbpa.2023.102401 37806262 41. Navas L.E. Carnero A. NAD+ metabolism, stemness, the immune response, and cancer Signal Transduct. Target. Ther. 2021 6 2 10.1038/s41392-020-00354-w 33384409 PMC7775471 42. Poon M.M.L. Caron D.P. Wang Z. Wells S.B. Chen D. Meng W. A Szabo P. Lam N. Kubota M. Matsumoto R. Tissue adaptation and clonal segregation of human memory T cells in barrier sites Nat. Immunol. 2023 24 309 319 10.1038/s41590-022-01395-9 36658238 PMC10063339 43. Williams J.B. Kupper T.S. Resident Memory T Cells in the Tumor Microenvironment Adv. Exp. Med. Biol. 2020 1273 39 68 10.1007/978-3-030-49270-0_3 33119875 44. Pan Y. Tian T. Park C.O. Lofftus S.Y. Mei S. Liu X. Luo C. O’Malley J.T. Gehad A. Teague J.E. Survival of tissue-resident memory T cells requires exogenous lipid uptake and metabolism Nature 2024 625 381 388 10.1038/nature21379 PMC5509051 28219080 45. Hirai T. Yang Y. Zenke Y. Li H. Chaudhri V.K. Diaz J.S.D.L.C. Zhou P.Y. Nguyen B.A.-T. Bartholin L. Workman C.J. Competition for Active TGFβ Cytokine Allows for Selective Retention of Antigen-Specific Tissue-Resident Memory T Cells in the Epidermal Niche Immunity 2021 54 84 98.e5 10.1016/j.immuni.2020.10.022 33212014 PMC7856016 46. Robert C. A decade of immune-checkpoint inhibitors in cancer therapy Nat. Commun. 2020 11 3801 10.1038/s41467-020-17670-y 32732879 PMC7393098 47. Park S.L. Gebhardt T. Mackay L.K. Tissue-Resident Memory T Cells in Cancer Immunosurveillance Trends Immunol. 2019 40 735 747 10.1016/j.it.2019.06.002 31255505 48. Zhang X. Sharma P.K. Goedegebuure S.P. Gillanders W.E. Personalized cancer vaccines: Targeting the cancer mutanome Vaccine 2017 35 1094 1100 10.1016/j.vaccine.2016.05.073 27449681 PMC5448976 49. Polack F.P. Thomas S.J. Kitchin N. Absalon J. Gurtman A. Lockhart S. Perez J.L. Pérez Marc G. Moreira E.D. Zerbini C. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine N. Engl. J. Med. 2020 383 2603 2615 10.1056/NEJMoa2034577 33301246 PMC7745181 50. Lin L. Ting S. Yufei H. Wendong L. Yubo F. Jing Z. Epitope-based peptide vaccines predicted against novel coronavirus disease caused by SARS-CoV-2 Virus Res. 2019 288 198082 10.1016/j.virusres.2020.198082 PMC7328648 32621841 51. Baden L.R. El Sahly H.M. Essink B. Kotloff K. Frey S. Novak R. Diemert D. Spector S.A. Rouphael N. Creech C.B. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine N. Engl. J. Med. 2021 384 403 416 10.1056/NEJMoa2035389 33378609 PMC7787219 52. Jackson L.A. Anderson E.J. Rouphael N.G. Roberts P.C. Makhene M. Coler R.N. McCullough M.P. Chappell J.D. Denison M.R. Stevens L.J. An mRNA vaccine against SARS-CoV-2—preliminary report N. Engl. J. Med. 2020 383 1920 1931 10.1056/NEJMoa2022483 32663912 PMC7377258 53. Van Hoecke L. Roose K. Ballegeer M. Zhong Z. Sanders N.N. De Koker S. Saelens X. Van Lint S. The Opposing Effect of Type I IFN on the T Cell Response by Non-modified mRNA-Lipoplex Vaccines Is Determined by the Route of Administration Mol. Ther. Nucleic. Acids. 2020 22 373 381 10.1016/j.omtn.2020.09.004 33230442 PMC7533292 54. Miao L. Zhang Y. Huang L. mRNA vaccine for cancer immunotherapy Mol. Cancer. 2021 20 41 10.1186/s12943-021-01335-5 33632261 PMC7905014 55. Karikó K. Buckstein M. Ni H. Weissman D. Suppression of RNA recognition by Toll-like receptors: The impact of nucleoside modification and the evolutionary origin of RNA Immunity 2008 23 165 175 10.1016/j.immuni.2005.06.008 16111635 56. Thess A. Grund S. Mui B.L. Hope M.J. Baumhof P. Fotin-Mleczek M. Schlake T. Sequence-engineered mRNA without chemical nucleoside modifications enables an effective protein therapy in large animals Mol. Ther. 2015 23 1456 1464 10.1038/mt.2015.103 26050989 PMC4817881 57. Verbeke R. Lentacker I. De Smedt S.C. Dewitte H. Three decades of messenger RNA vaccine development Nano Today 2019 28 100766 10.1016/j.nantod.2019.100766 58. Schoenmaker L. Witzigmann D. Kulkarni J.A. Verbeke R. Kersten G. Jiskoot W. Crommelin D.J. mRNA-lipid nanoparticle COVID-19 vaccines: Structure and stability Int. J. Pharm. 2021 601 120586 10.1016/j.ijpharm.2021.120586 33839230 PMC8032477 59. Hou X. Zaks T. Langer R. Dong Y. Lipid nanoparticles for mRNA delivery Nat. Rev. Mater. 2021 6 1078 1094 10.1038/s41578-021-00358-0 34394960 PMC8353930 60. Mitchell M.J. Billingsley M.M. Haley R.M. Wechsler M.E. Peppas N.A. Langer R. Engineering precision nanoparticles for drug delivery Nat. Rev. Drug Discov. 2021 20 101 124 10.1038/s41573-020-0090-8 33277608 PMC7717100 61. Mui B.L. Tam Y.K. Jayaraman M. Ansell S.M. Du X. Tam Y.Y.C. Lin P.J. Chen S. Narayanannair J.K. Rajeev K.G. Influence of polyethylene glycol lipid desorption rates on pharmacokinetics and pharmacodynamics of siRNA lipid nanoparticles Mol. Ther. Nucleic Acids 2013 2 e139 10.1038/mtna.2013.66 24345865 PMC3894582 62. Riley R.S. June C.H. Langer R. Mitchell M.J. Delivery technologies for cancer immunotherapy Nat. Rev. Drug Discov. 2019 18 175 196 10.1038/s41573-018-0006-z 30622344 PMC6410566 63. Cullis P.R. Hope M.J. Lipid nanoparticle systems for enabling gene therapies Mol. Ther. 2017 25 1467 1475 10.1016/j.ymthe.2017.03.013 28412170 PMC5498813 64. Leung A.K. Tam Y.Y.C. Chen S. Hafez I.M. Cullis P.R. Microfluidic mixing: A general method for encapsulating macromolecules in lipid nanoparticle systems J. Phys. Chem. B 2012 119 8698 8706 10.1021/acs.jpcb.5b02891 26087393 65. Reichmuth A.M. Oberli M.A. Jaklenec A. Langer R. Blankschtein D. mRNA vaccine delivery using lipid nanoparticles Ther. Deliv. 2016 7 319 334 10.4155/tde-2016-0006 27075952 PMC5439223 66. Young R.E. Hofbauer S.I. Riley R.S. Overcoming the challenge of long-term storage of mRNA-lipid nanoparticle vaccines Mol. Ther. 2022 30 1792 1793 10.1016/j.ymthe.2022.04.004 35452599 PMC9023316 67. Stadler C.R. Bähr-Mahmud H. Celik L. Hebich B. Roth A.S. Roth R.P. Karikó K. Türeci Ö. Sahin U. Elimination of large tumors in mice by mRNA-encoded bispecific antibodies Nat. Med. 2017 23 815 817 10.1038/nm.4356 28604701 68. Tan A.C. Goubier A. Kohrt H.E. A quantitative analysis of therapeutic cancer vaccines in phase 2 or phase 3 trial J. Immunother. Cancer 2022 3 7 10.1186/s40425-015-0093-x 26579225 PMC4647658 69. Feng C. Tan P. Nie G. Zhu M. Biomimetic and bioinspired nano-platforms for cancer vaccine development Exploration 2024 4 20230263 10.1002/EXP.20210263 PMC10624393 37933383 70. Yang M. Zhou J. Lu L. Deng D. Huang J. Tang Z. Shi X. Lo P. Lovell J.F. Zheng Y. Tumor cell membrane-based vaccines: A potential boost for cancer immunotherapy Exploration 2024 4 20230171 10.1002/EXP.20230171 39713208 PMC11655317 71. Oberli M.A. Reichmuth A.M. Dorkin J.R. Mitchell M.J. Fenton O.S. Jaklenec A. Anderson D.G. Langer R. Blankschtein D. Lipid nanoparticle assisted mRNA delivery for potent cancer immunotherapy Nano Lett. 2017 17 1326 1335 10.1021/acs.nanolett.6b03329 28273716 PMC5523404 72. Sahin U. Oehm P. Derhovanessian E. Jabulowsky R.A. Vormehr M. Gold M. Maurus D. Schwarck-Kokarakis D. Kuhn A.N. Omokoko T. An RNA vaccine drives immunity in checkpoint-inhibitor-treated melanoma Nature 2020 585 107 112 10.1038/s41586-020-2537-9 32728218 73. Sebastian M. Papachristofilou A. Weiss C. Früh M. Cathomas R. Hilbe W. Wehler T. Rippin G. Koch S.D. Scheel B. Phase Ib study evaluating a self-adjuvanted mRNA cancer vaccine (RNActive ® BMC Cancer 2014 14 748 10.1186/1471-2407-14-748 25288198 PMC4195907 74. Ndeupen S. Qin Z. Jacobsen S. Bouteau A. Estanbouli H. Igyártó B.Z. The mRNA-LNP platform’s lipid nanoparticle component used in preclinical vaccine studies is highly inflammatory iScience 2021 24 103479 10.1016/j.isci.2021.103479 34841223 PMC8604799 75. Pardi N. Tuyishime S. Muramatsu H. Kariko K. Mui B.L. Tam Y.K. Madden T.D. Hope M.J. Weissman D. Expression kinetics of nucleoside-modified mRNA delivered in lipid nanoparticles to mice by various routes J. Control. Release 2015 217 345 351 10.1016/j.jconrel.2015.08.007 26264835 PMC4624045 76. Blass E. Ott P.A. Advances in the Development of Personalized Neoantigen-Based Therapeutic Cancer Vaccines Nat. Rev. Clin. Oncol. 2021 18 215 229 10.1038/s41571-020-00460-2 33473220 PMC7816749 77. Weissman D. mRNA transcript therapy Expert Rev. Vaccines 2015 14 265 281 10.1586/14760584.2015.973859 25359562 78. Magoola M. Niazi S.K. Current Progress and Future Perspectives of RNA-Based Cancer Vaccines: A 2025 Update Cancers 2024 17 1882 10.3390/cancers17111882 40507360 PMC12153701 79. FDA Clinical Considerations for Therapeutic Cancer Vaccines U.S. Food and Drug Administration, Center for Biologics Evaluation and Research Silver Spring, MD, USA 2024 80. EMA Guideline on the Quality, Non-Clinical and Clinical Requirements for mRNA-Based Prophylactic Vaccines Against Infectious Diseases EMA/CHMP/BWP/814208/2024 EMA Amsterdam, The Netherlands 2024 81. Excler J.-L. Saville M. Berkley S. Kim J.H. Vaccine development for emerging infectious diseases Nat. Med. 2023 27 591 600 10.1038/s41591-021-01301-0 33846611 82. Sava J. FDA Clears IND Application for EVM14 Across Cancers FDA Silver Spring, MD, USA 2025 83. Singh P. Khatib M.N. Roopashree R. Kaur M. Srivastava M. Barwal A. Rajput G.V.S. Rajput P. Syed R. Sharma G. Advancements and challenges in personalized neoantigen-based cancer vaccines Oncol. Rev. 2025 19 1541326 10.3389/or.2025.1541326 40160263 PMC11949952 84. Bodner K. Irvine M. Kwong J. Mishra S. Disparities in COVID-19 clinical studies from high-income and low-middle-income countries Int. J. Infect. Dis. 2023 130 112 120 10.1016/j.ijid.2023.03.022 PMC10105623 37068582 85. World Economic Forum A Historic Leap in Cancer Vaccines—Here’s What You Need to Know World Economic Forum Geneva, Switzerland 2024 86. Kon E. Elia U. Peer D. Principles for designing an optimal mRNA lipid nanoparticle vaccine Curr. Opin. Biotechnol. 2022 73 329 336 10.1016/j.copbio.2021.09.016 34715546 PMC8547895 87. Abreu A.d.J.L.d. Mpande C.A.M. Helble M. Nicholson M.W. Cortés M.d.L.Á. Ponsa M.E.P. Blumenthal I.R. Caccavo F. Pippo T. Sanjuan J.R. Investment Opportunities for mRNA Technology in Low- and Middle-Income Countries: Key Findings and Future Perspectives Vaccines 2025 13 112 10.3390/vaccines13020112 40006659 PMC11861337 88. WHO Potential Benefits and Limitations of mRNA Technology for Vaccine Research and Development in Low- and Middle-Income Countries WHO Geneva, Switzerland 2023 89. Parhiz H. Atochina-Vasserman E.N. Weissman D. mRNA-based therapeutics: Looking beyond COVID-19 vaccines Lancet 2024 403 1192 1204 10.1016/S0140-6736(23)02444-3 38461842 90. Zolot R.S. Basu S. Million R.P. Antibody-drug conjugates Nat. Rev. Drug Discov. 2013 12 259 260 10.1038/nrd3980 23535930 91. Zhao P. Hou X. Yan J. Du S. Xue Y. Li W. Xiang G. Dong Y. Long-term storage of lipid-like nanoparticles for mRNA delivery Bioact. Mater. 2020 5 358 363 10.1016/j.bioactmat.2020.03.001 32206737 PMC7078456 92. Hegde P.S. Chen D.S. Systems immunology approaches for cancer therapy Cell 2024 187 1843 1861 10.1016/j.cell.2024.03.015 93. Whitehead K.A. Dorkin J.R. Vegas A.J. Chang P.H. Veiseh O. Matthews J. Fenton O.S. Zhang Y. Olejnik K.T. Yesilyurt V. Degradable lipid nanoparticles with predictable in vivo siRNA delivery activity Nat. Commun. 2014 5 4277 10.1038/ncomms5277 24969323 PMC4111939 94. Crager S.E. Improving global access to new vaccines: Intellectual property, technology transfer, and regulatory pathways Am. J. Public Health 2014 104 e85 e91 10.2105/AJPH.2014.302236 25211753 PMC4202949 95. Ott P.A. Hu Z. Keskin D.B. Shukla S.A. Sun J. Bozym D.J. Zhang W. Luoma A. Giobbie-Hurder A. Peter L. An immunogenic personal neoantigen vaccine for patients with melanoma Nature 2017 547 217 221 10.1038/nature22991 28678778 PMC5577644 96. Sahin U. Derhovanessian E. Miller M. Kloke B.-P. Simon P. Löwer M. Bukur V. Tadmor A.D. Luxemburger U. Schrörs B. Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer Nature 2017 547 222 226 10.1038/nature23003 28678784 97. Keskin D.B. Anandappa A.J. Sun J. Tirosh I. Mathewson N.D. Li S. Oliveira G. Giobbie-Hurder A. Felt K. Gjini E. Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial Nature 2019 565 234 239 10.1038/s41586-018-0792-9 30568305 PMC6546179 98. Hilf N. Kuttruff-Coqui S. Frenzel K. Bukur V. Stevanović S. Gouttefangeas C. Platten M. Tabatabai G. Dutoit V. Van Der Burg S.H. Actively personalized vaccination trial for newly diagnosed glioblastoma Nature 2019 565 240 245 10.1038/s41586-018-0810-y 30568303 Figure 1 Universal mRNA cancer vaccines alter the tumor microenvironment’s transformation. Figure 2 Epitope-spreading cascade enables broad antitumor immunity through progressive antigenic diversification. A: Stage 1; B: Stage 2. Figure 3 Integration of multiple immune activation pathways achieves synergistic antitumor effects. vaccines-13-00970-t001_Table 1 Table 1 Pattern Recognition Receptor Activation by Universal mRNA Vaccines. PRR Family Specific Receptor Activating Ligand Downstream Signaling Immunological Outcome References Toll-like Receptors TLR7/8 Single-stranded mRNA IRF7 → Type I IFN DC maturation, T cell priming [ 19 Toll-like Receptors TLR3 Double-stranded RNA TRIF → NF-κB Pro-inflammatory cytokines [ 20 RIG-I-like Receptors RIG-I 5′-triphosphate mRNA MAVS → IFN-β Antiviral response, DC activation [ 2 RIG-I-like Receptors MDA5 Long dsRNA MAVS → Type I IFN Amplified antiviral response [ 21 DNA Sensors cGAS-STING Mitochondrial DNA STING → Type I IFN T-cell cross-priming [ 22 DNA Sensors AIM2 Cytoplasmic DNA Inflammasome → IL-1β/IL-18 Th1/Th17 differentiation [ 23 NOD-like Receptors NLRP3 Ion flux, ROS Inflammasome → IL-1β Inflammatory amplification [ 2 NOD-like Receptors NLRC4 Flagellin peptides Inflammasome → IL-1β/IL-18 Enhanced DC function [ 24 vaccines-13-00970-t002_Table 2 Table 2 Temporal Dynamics and Detection Methods for Epitope Spreading. Time Point Cellular Events Detection Methods (Mouse) Detection Methods (Human) Key Markers References 0–6 h Initial PRR activation Serum cytokines (ELISA) Serum cytokines (Luminex) IFN-α/β, IL-6 [ 5 6–24 h DC activation Flow cytometry Flow cytometry (PBMC) CD40, CD80, CD86 [ 2 24–48 h Antigen processing MHC-peptide elution Mass spectrometry Peptide diversity [ 8 48–72 h T-cell priming ELISPOT ELISPOT, tetramer staining IFN-γ SFU [ 21 3–7 days B-cell activation BCR sequencing BCR deep sequencing Clonal diversity [ 28 7–14 days Epitope spreading Peptide arrays TCR sequencing New specificities [ 3 14–28 days Memory formation Tetramer staining Multimer analysis CD45RO + CCR7+ [ 23 28+ days Sustained immunity Rechallenge studies Clinical response Survival data [ 5 vaccines-13-00970-t003_Table 3 Table 3 Pathway Cross-talk in Universal mRNA Vaccines. Pathway Interaction Molecular Mechanism Net Effect Optimization Strategy Clinical Relevance References Type I IFN + NLRP3 IL-1β → NFκB → IFN genes Synergistic Sequential activation Enhanced efficacy [ 30 NLRP3 + cGAS-STING mtDNA release → STING Synergistic Controlled pyroptosis Amplified immunity [ 31 High IL-1β → Type I IFN STAT1 degradation Antagonistic IL-1β blockade Prevent exhaustion [ 32 Chronic inflammasome → DC function DC pyroptosis Antagonistic Pulsed dosing Maintain the APC pool [ 33 Complement + Inflammasome C5a → enhanced IL-1β Synergistic Complement inhibition Limit inflammation [ 34 vaccines-13-00970-t005_Table 5 Table 5 Strategies for Tissue-Resident Memory T-Cell Induction via mRNA Vaccines. Strategy Molecular Target Implementation TRM Markers Functional Outcomes References Route optimization Local delivery Intratumoral, orthotopic CD103 + CD69+ Local tumor control [ 42 Adhesion programming E-cadherin, CXCR6 mRNA co-delivery Tissue retention Prevents metastasis [ 43 Metabolic adaptation FABP4, FABP5 Lipid metabolism Survival in tissue Long-term protection [ 44 Epigenetic priming TGF-β signaling Local cytokine encoding Chromatin remodeling Stable phenotype [ 45 Checkpoint modulation PD-1 blockade Combination therapy Enhanced function Prevents exhaustion [ 46 vaccines-13-00970-t008_Table 8 Table 8 Mouse vs. Human Translation Considerations. Parameter Mouse Models Human Tumors Translation Factor Clinical Adaptation Tumor doubling time 2–3 days 50–200 days 15–50× slower Extended evaluation periods Immune response onset 7 days 14–28 days 2–4× slower Delayed biomarker assessment Epitope spreading 2–3 weeks 4–8 weeks 2–3× slower Extended immune monitoring Treg frequency 5–10% 15–30% 2–3× higher Combination with Treg depletion Checkpoint expression Moderate High 2–5× higher Checkpoint inhibitor combinations Treatment duration 2–4 weeks 3–6 months 6–12× longer Sustained dosing protocols vaccines-13-00970-t009_Table 9 Table 9 Preclinical Efficacy of Non-Tumor-Specific mRNA Vaccines in Multiple Cancer Models. Parameter Control Vaccine Alone Vaccine + Anti-PD-1 Model System References Tumor growth inhibition (%) 0 60 ± 10 85 ± 15 B16-F10 melanoma [ 2 78 Complete response rate (%) 0 30 ± 5 70 ± 10 B16-F10 melanoma [ 78 Median survival (days) 18 ± 2 31 ± 4 45 ± 6 B16-F10 melanoma [ 79 CD8+ TIL increase (fold) 1.0 ± 0.2 4.2 ± 1.1 6.5 ± 1.5 B16-F10 melanoma [ 79 IFN-γ+ TILs (%) 5 ± 2 22 ± 5 38 ± 7 B16-F10 melanoma [ 78 Rechallenge protection (%) 0 85 ± 5 95 ± 3 B16-F10 melanoma [ 80 Metastasis reduction (%) 0 45 ± 8 75 ± 12 4T1 breast cancer [ 81 Survival extension (%) 0 40 ± 10 70 ± 15 MC38 colon cancer [ 82 vaccines-13-00970-t010_Table 10 Table 10 Safety Profile Summary Across Preclinical Species. Safety Parameter Mouse (C57BL/6) NHP ( Macaca fascicularis Clinical Relevance Monitoring Plan Maximum tolerated dose >2000 μg/kg >1000 μg/kg 100-fold safety margin Dose escalation study Injection site reactions Minimal Mild, reversible Expected, manageable Local assessment Constitutional symptoms None observed Transient fever Likely in humans Symptom monitoring Liver enzyme elevation None Mild, reversible Monitor ALT/AST Weekly labs Cytokine elevation Marked (therapeutic) Moderate Expected mechanism Serial cytokine levels Autoimmune reactions None None observed Low risk ANA, organ-specific Ab Biodistribution concerns Liver predominant Similar pattern Consider dose/schedule Imaging if needed vaccines-13-00970-t011_Table 11 Table 11 Comparative Analysis of mRNA Cancer Vaccine Approaches. Feature Personalized Neoantigen Shared TAA Cytokine-Encoding Universal Non-Specific Time to Treatment 8–12 weeks Days-weeks Days-weeks Days Cost per Patient $100,000–200,000 $10,000–25,000 $15,000–30,000 $500–2000 Population Coverage Limited by HLA/mutations Moderate Broad >90% Manufacturing Complexity High (personalized) Moderate Moderate Low (standardized) Regulatory Pathway Complex (individual) Standard Standard Standard Efficacy (ORR) 15–25% (proven) 10–15% (proven) Unknown 30–40% (projected) Safety Profile Established Established Under evaluation Favorable (preclinical) Scalability Poor Moderate Moderate Excellent Global Access Very limited Limited Limited High potential Resistance Development High (antigen loss) Moderate Unknown Low (broad targeting) Combination Potential Moderate Moderate Limited High vaccines-13-00970-t012_Table 12 Table 12 Phase I Clinical Trial Schema. Study Component Specification Rationale Success Criteria Design Modified 3 + 3 dose escalation Standard oncology phase I MTD identification Starting dose 25 μg mRNA 1/20th of the predicted efficacious dose No DLTs in first cohort Dose levels 25, 50, 100, 200 μg 2-fold escalation steps Biological activity at ≤200 μg Primary endpoint Safety and tolerability Regulatory requirement <33% DLT rate at MTD Patient population Advanced solid tumors Adequate risk/benefit ratio Diverse tumor representation Sample size 24–48 patients Adequate for safety assessment Enroll within 18 months Treatment schedule Days 1, 15, 29, then q3monthly Prime-boost for optimal immunity ≥80% completion of induction Biomarker plan Comprehensive immune monitoring Mechanism confirmation Evidence of immune activation vaccines-13-00970-t013_Table 13 Table 13 Biomarker Assessment Timeline and Methods. Timepoint Sample Type Assays Primary Endpoints Clinical Utility Screening Blood, archival tissue HLA typing, TIS, TMB Patient stratification Enrollment criteria Baseline Blood, fresh tissue Comprehensive immune panel Predictive markers Patient selection 6 h Blood Cytokines, activation markers Immediate response Dose optimization 24 h Blood Gene expression, flow cytometry Early activation Mechanism confirmation Day 8 Blood T-cell responses, ELISPOT Immune priming Dose escalation Day 29 Blood, tissue Adaptive responses Vaccine immunogenicity Efficacy prediction Day 57 Blood Epitope spreading Mechanistic endpoint Proof of concept Every 2 cycles Blood Disease monitoring Clinical benefit Response assessment vaccines-13-00970-t014_Table 14 Table 14 Storage Solutions Development Timeline. Technology Development Status Stability Target Clinical Timeline Commercial Viability Current LNP (−70 °C) Established 24 months Available now Limited global access Lyophilized (2–8 °C) Development phase 12–24 months 2–3 years Moderate improvement Lyophilized (25 °C) Research phase 6–12 months 3–5 years Significant improvement Alternative systems Early research 12+ months (25 °C) 5+ years Game-changing potential Room temperature liquid Concept stage 6+ months (25 °C) 5+ years Ultimate goal vaccines-13-00970-t015_Table 15 Table 15 Challenge Prioritization and Mitigation Timeline. Challenge Category Impact Level Probability Mitigation Strategy Implementation Timeline Success Metrics Immunological pathway interference High Medium Systems biology modeling 2–3 years Optimized dosing protocols CRS/autoimmune toxicity High Low-Medium Enhanced monitoring/prophylaxis 1–2 years <5% severe AE rate Manufacturing scale-up Medium High Process automation/standardization 3–5 years 10M+ doses annually Regulatory harmonization Medium Medium Global coordination initiatives 2–4 years Multi-region approvals Cost optimization Medium High Process innovation 3–5 years <$100 per course Individual variability Medium High Personalized approaches 5–10 years Predictive algorithms vaccines-13-00970-t016_Table 16 Table 16 Development Timeline and Milestones. Timeframe Clinical Milestones Technical Achievements Regulatory Goals Access Targets 2–3 years Phase I completion, biomarker validation Improved formulations, delivery optimization FDA/EMA guidance Pilot manufacturing 3–5 years Phase II efficacy data Room temperature stability Regulatory submission Regional production 5–7 years First approval AI-optimized design Market authorization Global distribution 7–10 years Multiple indications Advanced delivery systems Combination approvals Cost optimization 10–15 years Prevention applications Predictive medicine Global harmonization Universal access ",
  "metadata": {
    "Title of this paper": "Actively personalized vaccination trial for newly diagnosed glioblastoma",
    "Journal it was published in:": "Vaccines",
    "URL": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12474334/"
  }
}